GW 9662
Tocris Bioscience, part of Bio-Techne | Catalog # 1508
Selective covalent PPARγ antagonist
Key Product Details
Description
Selective covalent PPARγ antagonist
Product Description
GW 9662 is a selective irreversible PPARγ antagonist (IC50 values are 3.3, 32 and 2000 nM for PPARγ, PPARα and PPARδ respectively). Blocks the inhibition of osteoclast formation induced by IL-4 in the low micromolar range (1-2 μM), therefore is more potent than BADGE. Anticancer, inhibits growth of human mammary tumor cell lines.Product Specifications
Molecular Weight
276.68
Formula
C13H9N2O3Cl
Storage
Store at RT
Purity
≥98% (HPLC)
Chemical Name
2-Chloro-5-nitro-N-phenylbenzamide
CAS Number
22978-25-2
PubChem ID
644213
InChI Key
DNTSIBUQMRRYIU-UHFFFAOYSA-N
SMILES
[O-][N+](=O)C1=CC(C(=O)NC2=CC=CC=C2)=C(Cl)C=C1
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Solubility
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 27.67 | 100 | |
| Ethanol | 6.92 | 25 with gentle warming |
Preparing Stock Solutions
for GW 9662
The following data is based on the product molecular weight 276.68
Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 3.61 mL | 18.07 mL | 36.14 mL |
| 5 mM | 0.72 mL | 3.61 mL | 7.23 mL |
| 10 mM | 0.36 mL | 1.81 mL | 3.61 mL |
| 50 mM | 0.07 mL | 0.36 mL | 0.72 mL |
Calculators
Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Background References
References are publications that support the biological activity of the product.
- Leesnitzer Functional consequences of cysteine modification in the ligand binding sites of peroxisone proliferator activated receptors by GW9662. Biochemistry 2002 PMID: 12022867
- Seargent GW9662, a potent antaognist of PPARγ, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARγ agonist rosiglitazone, independently of PPARγ activation. Br.J.Pharmacol. 2004 PMID: 15533890
- Bendixen IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor γ1. Proc.Natl.Acad.Sci.U.S.A. 2001 PMID: 11226258
Product Specific Notices for GW 9662
For research use only
Loading...
Loading...
Loading...